Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020

July 2020 | 72 pages | ID: CB570207AE8EN
Global Markets Direct

Abstracts

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2020, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.
Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Cluster Headache Syndrome (Cluster Headache) - Overview
Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
CCH Pharmaceuticals ApS
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
Mind Medicine Inc
NeuroPharm Inc
TrioxBio Inc
Winston Pharmaceuticals Inc
Zosano Pharma Corp
Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
CLE-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
Cluster Headache Syndrome (Cluster Headache) - Discontinued Products
Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2020: Phase 2 clinical trial of LSD for "Suicide Headaches" begins treating patients
Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality
Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
Jun 05, 2019: FDA approves first drug for episodic cluster headaches
May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio
Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults
Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by CCH Pharmaceuticals ApS, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Mind Medicine Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by NeuroPharm Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Winston Pharmaceuticals Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Zosano Pharma Corp, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

CCH Pharmaceuticals ApS
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
Mind Medicine Inc
NeuroPharm Inc
TrioxBio Inc
Winston Pharmaceuticals Inc
Zosano Pharma Corp